NCT04133636 2026-03-17
CARTITUDE-2
Janssen Research & Development, LLC
Phase 2 Active not recruiting
Clinical Trials
162 trialsNCT04634552 2026-03-17
MonumenTAL-1
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT06577025 2026-03-13
aMMbition
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT07149857 2026-03-13
CARTITUDE-10
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT07266441 2026-03-13
TRIlogy-3
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT07284758 2026-03-12
MOMENTUM
C4 Therapeutics, Inc.
Phase 2 Recruiting
NCT03601078 2026-03-04
KarMMa-2
Celgene
Phase 2 Completed
NCT05090566 2026-02-23
MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma
Pfizer
Phase 2 Active not recruiting
NCT05955508 2026-02-23
A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma
Regeneron Pharmaceuticals
Phase 2 Active not recruiting
NCT06500884 2026-02-13
Talisman
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT05561751 2026-02-12
Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant
GPCR Therapeutics, Inc.
Phase 2 Completed
NCT04977024 2026-02-11
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
GeoVax, Inc.
Phase 2 Active not recruiting
NCT05396885 2026-02-11
iMMagine-1
Gilead Sciences
Phase 2 Active not recruiting
NCT05014412 2026-02-10
MagnetisMM-9
Pfizer
Phase 2 Completed
NCT06297226 2026-02-10
QUINTESSENTIAL
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2 Recruiting
NCT04414475 2026-02-02
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.
Karyopharm Therapeutics Inc
Phase 2 Recruiting
NCT05172596 2026-01-13
PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma
Novartis
Phase 2 Terminated
NCT05228470 2026-01-06
A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
Pfizer
Phase 2 Completed
NCT07312188 2025-12-31
A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Shandong New Time Pharmaceutical Co., LTD
Phase 2 Recruiting
NCT05704049 2025-12-29
IZALCO
Sanofi
Phase 2 Active not recruiting
NCT03758417 2025-12-17
CARTIFAN-1
Nanjing Legend Biotech Co.
Phase 2 Terminated
NCT04649359 2025-12-02
MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
Pfizer
Phase 2 Active not recruiting
NCT07227311 2025-11-12
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
GlaxoSmithKline
Phase 2 Not yet recruiting
NCT04126200 2025-11-06
DREAMM5
GlaxoSmithKline
Phase 2 Active not recruiting
NCT05064358 2025-10-07
DREAMM 14
GlaxoSmithKline
Phase 2 Active not recruiting
NCT04191616 2025-09-04
SELECT
Amgen
Phase 2 Completed
NCT03525678 2025-09-03
A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody
GlaxoSmithKline
Phase 2 Completed
NCT03628612 2025-08-07
Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells
Autolus Limited
Phase 2 Enrolling by invitation
NCT02899052 2025-08-05
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)
AbbVie
Phase 2 Active not recruiting
NCT01946477 2025-06-06
POM MM 014
Celgene
Phase 2 Completed
NCT02719613 2025-06-05
Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab
Bristol-Myers Squibb
Phase 2 Active not recruiting
NCT03361748 2025-05-23
KarMMa
Celgene
Phase 2 Completed
NCT04176380 2025-05-15
RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma
Rapa Therapeutics LLC
Phase 2 Completed
NCT04892446 2025-05-02
Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
Gilead Sciences
Phase 2 Terminated
NCT03412565 2025-04-29
A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
Janssen Research & Development, LLC
Phase 2 Completed
NCT02316106 2025-04-27
A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma
Janssen Research & Development, LLC
Phase 2 Completed
NCT05347485 2025-04-25
A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma
Janssen Scientific Affairs, LLC
Phase 2 Completed
NCT03860038 2025-04-24
TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
TJ Biopharma Co., Ltd.
Phase 2 Completed
NCT03871829 2025-03-30
Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab
Janssen Research & Development, LLC
Phase 2 Terminated
NCT02924272 2025-03-12
Ixazomib Rollover Study
Takeda
Phase 2 Completed
NCT06668792 2025-02-04
FLAMMINGO
Biocad
Phase 2 Recruiting
NCT05669989 2025-01-23
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
Sanofi
Phase 2 Active not recruiting
NCT04782687 2025-01-16
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
US Oncology Research
Phase 2 Active not recruiting
NCT06115135 2025-01-16
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Oncotherapeutics
Phase 2 Recruiting
NCT04436029 2024-12-03
Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
Cartesian Therapeutics
Phase 2 Completed
NCT04816526 2024-10-08
Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
Cartesian Therapeutics
Phase 2 Terminated
NCT00747123 2024-10-03
A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma
Celgene
Phase 2 Completed
NCT02654990 2024-07-12
PANORAMA_3
pharmaand GmbH
Phase 2 Completed
NCT03439293 2024-07-03
A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)
Takeda
Phase 2 Completed
NCT05493800 2024-05-29
Capella
MitoImmune Therapeutics
Phase 2 Active not recruiting